[Therapeutic effects of hTR-siRNA adenovirus on human cervical cancer xenografts in nude mice].

ABSTRACT

OBJECTIVE: To study the anti-tumor effects and its mechanism of hTR-siRNA adenovirus on human cervical cancer in vivo. METHODS: The in vivo model of human cervical cancer was established by the subcutaneous inoculation of HeLa cells at the right armpit of BALB/c nu/nu mice. After successful implantation, the mice were randomized into four groups, in which the mice were intratumorally injected with 0.1 mL of Ad-hTR-siRNA (10(13) pfu/L), or Ad-NT-siRNA (10(13) pfu/L), or Cisplatin (1.20 g/L), or serum-free DMEM alone respectively. These treatments were given once every 3 days for 6 times. After the last injection, the mice were observed for 7 days continuously and sacrificed at the end. The tumors were harvasted, weighed, and sectioned. The TUNEL assay was used to assess the apoptosis of these tumor cells. RESULTS: Tumors-implanted were established successfully by 100% with HeLa cells. As compared with Ad-NT-siRNA, Ad-hTR-siRNA could slow down tumor growth, decrease tumor volume (45.48%) and tumor weight (34.68%), as well as promote the apoptosis and necrosis of tumor cells. The TUNEL positive cells were about 11.8%. But the anti-tumor activity of Ad-hTR-siRNA didn't catch on Cisplatin's. CONCLUSION: This study indicated that the hTR-siRNA adenovirus could suppress cervical cancer-xenografted growth in vivo and induce tumor cell apoptosis or necrosis.